ReviewHuman vaccines & immunotherapeutics2015
Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.
Review in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 103 citations in OpenAlex.
- Efficient Production of Swine Influenza Virus Using Serum-Free Suspension MDCK Cells for Vaccine Manufacturing.Journal of microbiology and biotechnology · 2026Article
- From Global Insights to Local Action: Bridging Vaccine Design and Manufacturing Gaps in H5N1 Pandemic Readiness.Vaccines · 2026Article
- Developing an oncolytic Newcastle disease virus production process with EB66 cells.Applied microbiology and biotechnology · 2026Article
- Comparative analysis of cellular immune responses to four seasonal inactivated influenza vaccines in younger and older adults.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Systemic removal of host restriction factors enables rapid, scalable virus production for cell culture-based vaccine development.Frontiers in bioengineering and biotechnology · 2026Article
- Chronic Diseases and Influenza Vaccines.Vaccines · 2025Review
- Article
- Evaluation of the Immune Effect of a Trivalent Fowl Adenovirus Inactivated Vaccine Against FAdV-4/8a/8b.Veterinary sciences · 2025Article
- MF59-like adjuvant containing yeast-derived squalene enhances the humoral immune response to cell-derived influenza vaccine.Archives of virology · 2025Article
- The global burden of swine influenza and its mitigation.Open veterinary journal · 2025Review
- Innovations in cell culture-based influenza vaccine manufacturing - from static cultures to high cell density cultivations.Human vaccines & immunotherapeutics · 2024Review
- Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.Vaccine · 2024Review
- Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens.Journal of biomedical science · 2024Review
- A synthetic TLR4 agonist significantly increases humoral immune responses and the protective ability of an MDCK-cell-derived inactivated H7N9 vaccine in mice.Archives of virology · 2024Article
- A comprehensive comparison of DNA and RNA vaccines.Advanced drug delivery reviews · 2024Review
- Article
- Replication kinetics of novel swine influenza A viruses: an approach to vaccine production.Austral journal of veterinary sciences · 2024Article
- From single-cell cloning to high-yield influenza virus production - implementing advanced technologies in vaccine process development.Engineering in life sciences · 2024Article
- Synthetic Cell Lines for Inducible Packaging of Influenza A Virus.ACS synthetic biology · 2024Article
- Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture-derived H5N1 (aH5n1c) influenza vaccine in adults and older adults.Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The traditional platform of using embryonated chicken eggs for the production of influenza vaccines has several drawbacks including the inability to meet the volume of required doses in the case of widespread epidemics and pandemics. Cell culture platforms have therefore been explored in the last 2 decades, and have attracted further attention following the H1N1 pandemic outbreak. This platform, while not the most economical for large-scale production, has several advantages, and can supplement the vaccine requirement when needed. Recent developments in production technologies have contributed greatly to fine-tuning this platform. In combination with other technologies such as live attenuated and recombinant protein or virus-like particle vaccines, and different adjuvants and delivery systems, cell culture-based influenza vaccine platform can be used both for production of seasonal vaccine, and to mitigate vaccine shortages in pandemic situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.